Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

Cancer
Jarrod P HolmesGeorge E Peoples

Abstract

E75, a HER-2/neu-derived peptide, was administered as a preventive vaccine with granulocyte-macrophage-colony-stimulating factor (GM-CSF) in disease-free lymph node-positive (NP) and lymph node-negative (NN) breast cancer (BCa) patients. The optimal biologic dose (OBD) was determined based on toxicity and immunologic response. Patients were vaccinated over 6 months (3, 4, or 6 times) with different doses of E75 plus GM-CSF. Toxicities were graded per National Cancer Institute Common Terminology Criteria. GM-CSF was reduced for significant toxicity. Immunologic response was measured by delayed type hypersensitivity test (DTH), and E75-specific CD8+ T-cells were quantified with human leukocyte antigen-A2:immunoglobulin G dimer and flow cytometry. Ninety-nine patients (48 NP and 51 NN) were vaccinated in 7 dose groups. The OBD was 1000 microg E75 plus 250 microg GM-CSF monthly x 6. The optimal dose group (ODG, n = 29) experienced similar toxicities to the suboptimal dose group (SDG, n = 70), which was comprised of the remaining 6 groups. The ODG demonstrated a trend toward an increase in the average postvaccine dimer (0.87 +/- 0.10% vs 0.67 +/- 0.05%; P = .07), a significantly larger DTH response (21.5 +/- 2.5 mm vs 11.3 +/- 1.3 m...Continue Reading

Associated Clinical Trials

References

Sep 4, 1975·The New England Journal of Medicine·J E Sokal
Jan 17, 1995·Proceedings of the National Academy of Sciences of the United States of America·G E PeoplesT J Eberlein
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T W JacobsS J Schnitt
Apr 13, 2002·Journal of the American College of Surgeons·Funda MericKelly K Hunt
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary L DisisKathy Schiffman
May 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary L DisisMartin A Cheever
Jul 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David AviganDonald Kufe
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Craig L SlingluffPriscilla Merrill
Sep 15, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George E PeoplesSathibalan Ponniah
Oct 11, 2005·Cancer Treatment and Research·Jay A BerzofskyMasaki Terabe
Oct 26, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew T HuemanGeorge E Peoples
Apr 13, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Craig L SlingluffSoldano Ferrone
Nov 23, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ParmianiL Rivoltini
Jan 2, 2007·Journal of Immunotherapy·Axel HoosUNKNOWN Cancer Vaccine Clinical Trial Working Group
Feb 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George E PeoplesSathibalan Ponniah

❮ Previous
Next ❯

Citations

Aug 23, 2012·Archivum Immunologiae Et Therapiae Experimentalis·Kyle K Payne, Masoud H Manjili
Nov 26, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michel AdaminaPaul Zajac
Nov 30, 2011·Nature Reviews. Clinical Oncology·Carlos L ArteagaLuca Gianni
Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MilaniG Valabrega
Sep 17, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Nathan M ShumwayJames L Murray
Dec 21, 2012·Expert Review of Anticancer Therapy·Leisha A Emens
Dec 10, 2008·Expert Opinion on Biological Therapy·Elizabeth A MittendorfGeorge E Peoples
Feb 21, 2009·Journal of the American College of Surgeons·Jeremy D GatesGeorge E Peoples
Mar 12, 2016·Nature Reviews. Cancer·Sjoerd H van der BurgCornelis J M Melief
Sep 23, 2009·Annals of the New York Academy of Sciences·Neil L Berinstein
Jul 22, 2014·Cancer Science·Yoshiyuki YamaguchiUNKNOWN Committee of Guidance for Peptide Vaccines for the Treatment of Cancer, The Japanese Society for Biological Therapy
Nov 17, 2015·Immunotherapy·Guy T CliftonGeorge E Peoples
Apr 6, 2016·Future Oncology·Guy T CliftonElizabeth A Mittendorf
Aug 21, 2013·Human Vaccines & Immunotherapeutics·Lingxiao ZhaoHua Cong
Feb 14, 2015·Current Oncology Reports·Brenda Ernst, Karen S Anderson
Nov 2, 2016·Expert Opinion on Biological Therapy·Elham Beyranvand NejadSjoerd H van der Burg
Dec 30, 2014·Breast Cancer Research and Treatment·N ElsterB T Hennessy
Nov 22, 2017·Journal for Immunotherapy of Cancer·Patrick M DillonCraig L Slingluff
Nov 17, 2017·Cancer Immunology, Immunotherapy : CII·Jay A BerzofskyLauren V Wood
May 29, 2014·Expert Review of Clinical Immunology·Elham MohitMojgan Allahyari
Dec 4, 2016·Cancer Metastasis Reviews·Alison Spellman, Shou-Ching Tang
Dec 20, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michiko HaraoLaszlo G Radvanyi
Apr 9, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Linda C BenavidesGeorge E Peoples
Feb 4, 2021·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Homa SeyedmirzaeiNima Rezaei
Dec 6, 2019·Chemical Reviews·Ryan J MalonisOlivia Vergnolle
Mar 20, 2018·Current Opinion in Immunology·Hoyoung MaengJay A Berzofsky
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A MilaniG Valabrega

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.